Featured

Finding the right combination: new insights in anti-PD-1 plus anti-CTLA-4 or anti-LAG3

Treatment with checkpoint blockades alone or in various combinations can induce strong antitumor responses, but identifying which treatment or combination will work best for each individual patient is still a challenge. In work recently published in...

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

CD22.BBz CAR T cells had reduced ERK/MAPK and LAT signaling and were less effective against NALM6CD22low than NALM6WT tumors. To rescue efficacy, Pham-Danis et al. developed a dual CAR platform (ALA-C...

Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response

Analyzing scRNAseq data from 38 patients with gastric cancer (GC), Song, Wei, Liu, et al. identified antigen-presenting CAF (apCAF) with high MHC-II expression that spatially localized near tertiary l...

Continuous expression of TOX safeguards exhausted CD8 T cell epigenetic fate

Huang et al. demonstrated that inducible TOX deletion in established LCMV-specific exhausted T cells (Tex) after chronic infection impaired their durability and differentiation. Sustained TOX expressi...

Design of high-affinity binders to immune modulating receptors for cancer immunotherapy

Yang et al. developed, de novo, an array of concave helical protein scaffolds with diverse shapes and surfaces, high stability, and small sizes, with the goal of enabling them to be combined to target...

See all for this week

Previous Digests

Tumoral RNA splicing: source of neoantigens for off-the-shelf therapies?

March 12, 2025

Immunotherapies targeting tumor-specific antigens (TSAs) derived from somatic mutations have limited potential in tumors with low mutational burdens. A recently discovered source of TSAs are cancer-specific splicing events (neojunctions; NJs), which have the potential to induce CD8+ T cell...

AACR IO 2025

March 5, 2025

The ACIR team attended the newly established AACR IO meeting held on February 23-26, 2025 in Los Angeles, CA, USA. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below...

TLR agonism and PD-1 blockade unfortunately activate suppressor cells

February 26, 2025

The activation of an immune response involves a system of checks and balances. While immunotherapies can be used to tip the scales, they are not always effective, as resistance mechanisms may act to counter desired responses. In research recently...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ute Burkhardt

Lauren Hitchings

Gaelle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

— Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Testimonials